Immunoreactive glycoprotein GP19 Ehrlichia canis

Patent metadata

Field	Value
Publication number	US-9605032-B2
Application number	US-37792607-A
Country	US
Kind code	B2
Filing date	Aug 7, 2007
Priority date	Aug 31, 2006
Publication date	Mar 28, 2017
Grant date	Mar 28, 2017

Abstract

The present invention concerns gp19 immunoreactive compositions for E. canis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. canis gp19 are disclosed.

First claim

What is claimed is:

1. A composition comprising an isolated polypeptide that is from 24 to 75 amino acids in length, said polypeptide being selected from the group consisting of:
(a) an isolated polypeptide comprising SEQ ID NO:13; and
(b) an isolated polypeptide that is at least 95% identical to SEQ ID NO:13;

wherein the isolated polypeptide is bound to a solid support or a detectable label.

2. The composition of claim 1 , wherein the polypeptide comprises one or more carbohydrate moieties.

3. An isolated antibody that recognizes and binds immunologically to a polypeptide that consists of SEQ ID NO:13 or a polypeptide that is at least 95% identical to such a polypeptide, wherein the antibody is either bound to a solid support or a detectable label.

4. The antibody of claim 3 , wherein said antibody is a monoclonal antibody, is comprised in polyclonal antisera, or is an antibody fragment.

5. A kit, comprising the following compositions:
(a) the polypeptide composition of claim 1 ; and
(b) an isolated antibody that recognizes and binds immunologically to a polypeptide composition that is from 24 to 75 amino acids in length comprising SEQ ID NO:13 or with a polypeptide that is at least 95% identical to such a polypeptide.

6. The polypeptide composition of claim 1 , wherein said polypeptide is dispersed in a pharmaceutically acceptable diluent.

7. The polypeptide composition of claim 1 , wherein the polypeptide is bound to a solid support.

8. The polypeptide composition of claim 7 , wherein the solid support is a column matrix, a well of a microtiter plate, a dot blot membrane or a Western blot membrane.

9. The polypeptide composition of claim 1 , wherein the polypeptide is bound to a detectable label.

10. The kit of claim 5 , wherein the isolated antibody is bound to a detectable label.

11. The kit of claim 5 , wherein the detectable label is a second antibody that binds to the isolated antibody.

12. The isolated antibody of claim 3 , wherein the antibody is bound to a detectable label.

13. The isolated antibody of claim 12 , wherein the detectable label is an enzyme.

Assignees

• Mcbride Jere W
• Doyle Christopher K
• Res Dev Foundation

Inventors

• Mcbride Jere W
• Doyle Christopher K

Classifications

• C07K16/1246

  Rickettsiales (O) · CPC title

• G01N2800/26

  Infectious diseases, e.g. generalised sepsis · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• G01N33/56911

  Bacteria · CPC title

• A61K2039/552

  Veterinary vaccine · CPC title